Published in Clinical Oncology Week, May 16th, 2005
"This study determined the efficacy and safety of a modified FOLFOX regimen that improved patient convenience without compromising oxaliplatin dose intensity. A total of 62 patients with previously untreated metastatic colorectal cancer were enrolled to receive, entirely as outpatients, 2-weekly cycles of oxaliplatin 100 mg/m2 i.v. over 2 h, together with leucovorin 400 mg/m2 over 2 h, 5-fluorouracil (5-FU) 400 mg/m2, bolus, followed by a 46-h infusion of 5-FU at 2.4 g/m2," scientists reported in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.